Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR p.L858R status confers therapeutic sensitivity to Carboplatin, Osimertinib, Pemetrexed in patients with Non-Small Cell Lung Cancer.
Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
This statement is based on a regulatory approval from the Health Canada:
TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.